News

HDA UK Media And Political Bulletin – 1 March 2017

Media Summary

Operational Productivity: Hospital Pharmacy and Medicines Optimisation, Stakeholder Update, February 2017

NHS Improvement, 28 February 2017

The Hospital Pharmacy and Medicines Optimisation project (HoPMOp) team is now receiving board-approved HPTP plans from non-acute specialist trusts, hoping that most of these will be submitted by the end of March and reviewed to identify common themes where further support may be beneficial. Other developments include the drafting of an NHS Improvement top ten medicines list, which is likely to be published on the Model Hospital portal during April 2017, and the expansion of the NHS Improvement Getting It Right First Time programme. Recommendations have also arisen from a 2016 audit of discharge summaries. The final report suggests that there are still significant gaps in sharing information and reconciling medicines when a patient is discharged from hospital.

Safety Features Newsletter

MHRA, 28 February 2017

As part of their stakeholder engagement work, the MHRA has set up a dedicated email to receive enquiries about the implementation of the safety features aspect of the Falsified Medicines Directive (FMD). They have also confirmed that the Delegated Regulation does not make any reference to linear barcodes, therefore it is necessary to consider whether customers still require the linear barcodes to manage supply of the medicine within the specific sector of the supply chain. Further to the FMD, a website containing information to help community pharmacists prepare for the introduction of the FMD safety features has been launched.

Proposed regulations on medical Devices and in vitro diagnostic Medical Devices Regulations – updates

GIRP, 28 February 2017

Following the 2016 proposed regulations on the medical device and in vitro diagnostic medical devices, the final version of the two proposed regulations, as approved by the Council of the EU after the first reading on 22 February 2017, have been released. These considered that a fundamental revision of the medical devices directives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation. The GIRP team will monitor developments.

Parliamentary Coverage

House of Commons, Written Answer, Tuesday 28 February 2017, European Medicines Agency

Stephen Timms, MP:

To ask the Secretary of State for Health, what his Department’s policy is on the UK’s relationship with the European Medicines Agency after the UK leaves the EU.

Answered by Department of Health

David Mowat, MP:

The Government is fully assessing how the United Kingdom’s decision to leave the European Union will impact on medicines regulation in the UK, including the potential relocation of the European Medicines Agency (EMA). Whatever the future relationship between the UK and EMA, the Government will work to ensure that patient access to medicines will not be adversely impacted.

House of Commons, Written Answer. Tuesday 28 February, Patients: Medical Equipment

Oliver Colvile, MP:

To ask the Secretary of State for Health, what advice is given to patients and families of deceased patients who no longer require prescribed medicines, aids and medical equipment.

Answered by Department of Health

David Mowat , MP:

Disposal of waste medicines is an essential service within the community pharmacy contractual framework, to be provided by all community pharmacies in England. NHS England is responsible for commissioning National Health Service pharmaceutical services.

Patients are normally advised to return unused medicines to their local community pharmacy for safe disposal. This is the case also for patients and families of deceased patients who no longer require prescribed medicines.

Appliances are normally collected by community nurses. Occasionally there is a local amnesty with appeals to patients to return equipment, for example crutches and wheelchairs to accident and emergency departments.

Full Coverage

Operational Productivity: Hospital Pharmacy and Medicines Optimisation, Stakeholder Update, February 2017

NHS Improvement, 28 February 2017

This Hospital Pharmacy and Medicines Optimisation project (HoPMOp) stakeholder update provides information and updates for external stakeholders from the team implementing the recommendations of the review of NHS productivity and efficiency by Lord Carter.

HPTP planning process

Board approved HPTP plans are now beginning to arrive back with the HoPMOp team from acute non-specialist trusts. We are hoping that the majority of these will be submitted by the end of March and these will then be reviewed by the team to identify common themes, linked to the Carter recommendations, where further collaboration and support may be beneficial.

HoPMOp programme and team

Andrew Davies, currently Chief Pharmacist at North Bristol NHS trust, will become the professional pharmacy lead for the existing HoPMOp work programme. Seventeen specialist hospital trusts have also been invited to join the Hospital Pharmacy and Medicines Optimisation programme. Initial contact has been made with the trusts concerned who will be invited to send representatives to an orientation event during March 2017.

Top 10 medicines update

The governance processes to support the development and publication of an NHS Improvement top ten medicines list have been drafted and are the subject of a consultation with stakeholders. It is anticipated that this process will be completed imminently with the first “live” list scheduled for publication through the Model Hospital portal during April 2017.

Getting it right first time

The NHS Improvement Getting It Right First Time (GIRFT) programme is being expanded. Having started as a pilot within orthopaedic surgery and then expanded to a further 10 medical specialities, the GIRFT methodology and process has now been extended to a total of more than 30 medical and clinical specialities. The programme is in the process of appointing clinical leads for each speciality.

Job planning and eRostering

We are looking to work with a number of trusts who are already making progress with or thinking about clinical pharmacy job planning, particularly approaches to eRostering.

Regional Medicines Optimisation Committees

The HoPMOp team is working closely with colleagues in NHS England and NHS Clinical Commissioners to support the establishment of regional medicines optimisation committees. There have been four national engagement workshops held during February and work is now underway to formally establish the committees and agree priorities for the work programme. This is likely to focus on key medicines optimisation topics in consultation with NHS stakeholders.

Advice on Advanced Therapy Medicinal Products (ATMPs)

The National Pharmaceutical Quality Assurance Committee and the National Pharmacy Clinical Trials Advisory Group have published a joint document on ATMPs for Chief Pharmacists. Since ATMPs are medicines they are subject to the same requirements as for other medicinal products and the Chief Pharmacist is responsible for their governance and management. A full version of the document will be posted on the Specialist Pharmacy Service website.

CPPE support for hospital pharmacy and medicines optimization

CPPE has recently published a summary of materials and products that support hospital pharmacy and medicines optimisation. The brochure covers wide range of topics such as therapeutics, the Carter Report, leadership and workforce development and also includes links to relevant CPPE learning programmes.

BOPA position statement and guidance on biosimilars

The British Oncology Pharmacy Association (BOPA) has issued a position statement on the implementation of biosimilar monoclonal antibodies alongside a comprehensive guide on the important role that pharmacy plays in implementation.

Cost savings calculator

UKMI has updated its cost-savings calculator for use as a tool when setting local drugs budgets. Based on Microsoft Excel, the worksheets provide summaries of already-released and pending NICE technology appraisals and interventions. The tool is intended to be used alongside Prescribing Outlook – National Developments.

Medicines reconciliation

In 2016, the medicines use and safety team from the Specialist Pharmacy Service undertook a collaborative audit of over 1,400 discharge summaries (over 10,000 medicines) to assess the quality of medicines information provided. The final report suggests that there are still significant gaps in sharing information and reconciling medicines when a patient is discharged from hospital.  For example, less than 12% of summaries included an indication for the medicine prescribed and only three-quarters correctly documented allergy status. The reports makes a number of recommendations for hospital pharmacists.

Sourcing ready-made chemotherapy

This guide published by the NHS Pharmaceutical Quality Assurance Committee and BOPA is available to registered users. It contains useful information on dose-banding as well as guidance on the sourcing of ready-to-administer doses.

Antifungal stewardship

Antifungals are essential in modern healthcare due to the increased incidence of invasive fungal infections linked to immunosuppression and the widespread use of invasive devices. Despite their costs, the quality of antifungal prescribing is poor leading to unnecessary usage, the wrong choice of antifungal and suboptimal duration of treatment. NHS Improvement is working with colleagues in Public Health England to consider an appropriate metric for future inclusion in the Model Hospital dashboard.

 

Safety Features Newsletter

MHRA, 28 February 2017

New Mailbox for FMD enquiries

As part of our stakeholder engagement work we have set up a dedicated email mailbox to receive enquiries about the implementation of the safety features aspect of the Falsified Medicines Directive.  The mailbox is monitored daily and you can expect to receive a response within 5 working days.   Please contact us at FMD.safetyfeatures@mhra.gsi.gov.uk

Linear barcodes – can they remain

We have been asked whether the current linear EAN barcodes which are present on most packs can remain or have to be removed under the new requirements.  The Delegated Regulation does not make any reference to linear barcodes.  You will need to consider whether your customers still require the linear barcodes to manage supply of the medicine within their sector of the supply chain.   When you submit your notification to advise us that you will be adding the 2D data matrix code to your pack we will not expect you to remove the linear barcode at that time.  It may be that in the future the linear code will become redundant and you will want to remove it.  That can be done at any suitable regulatory intervention.   The regulatory guidance on how to submit updates to marketing authorisations impacted by the FMD safety features can be found here.

Community pharmacy resources

A website containing information to help community pharmacists prepare for the introduction of the FMD safety features.  It has been launched by the UK FMD working group for community pharmacy which includes representatives of the all the main bodies in community pharmacy.   This link will take you to the website.

Difference between decommissioning and verification

Verification can take at any time during the movement of the medicine through the supply chain.  It is a check of the repository (IT database) that the product is authentic and originates from a legitimate manufacturer.  Decommissioning takes places at the end of the supply chain when the product is being supplied to the patient and closes the unique identifier in the repository – so that any other pack bearing the same unique identifier cannot successfully be verified/or decommissioned.

HDA UK Media And Political Bulletin – 1 March 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?